Navigation Links
Regado Biosciences to Present at the Annual UBS Global Life Sciences Conference in New York City
Date:9/14/2011

BASKING RIDGE, N.J., Sept. 14, 2011 /PRNewswire/ -- Regado Biosciences, a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced that Ellen McDonald, MBA, Senior Vice President and Chief Business Officer, will be presenting at the Annual UBS Global Life Sciences Conference at the Grand Hyatt New York in New York City on Wednesday, September 21, 2011 at 3:30 p.m. EDT.  The presentation will include an overview of the Company's pipeline with emphasis on the lead development program, the innovative anticoagulant system REG1, including a summary of the REG1 phase 2b trial (RADAR) results.    

ABOUT REGADO BIOSCIENCES

Regado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent.  This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, providing a safe and unique approach to personalized medicine.

ABOUT REG1, REG2 and REG3  

Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (pegnivacogin, a.k.a. RB006)
'/>"/>

SOURCE Regado Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
2. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
3. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
4. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
5. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
6. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
7. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
8. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
9. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
10. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
11. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... The global Bioinformatics ... sectors, products & services and application. And the rising ... increasing demand of advanced drugs for the diagnosis ... growth for bioinformatics market. The implementation of information ... as bioinformatics. Decreasing cost of DNA sequencing, continuous ...
(Date:9/1/2015)... Research and Markets ( http://www.researchandmarkets.com/research/r8v22b/regulatory ) has announced the ... (London, UK - September 24-25, 2015)" conference to ... provides an introduction to Pharmaceutical Regulatory Affairs and the ... for those working in a support staff role. ... regulatory procedures required to register products in ...
(Date:9/1/2015)... , September 1, 2015 - ... GARFIELD-AF R egistry data presented at ... on the evolution of manag ... -   The first-ever two-year outcomes from ... ESC Congress 2015 expose that all-cause death was the most frequent major event ...
Breaking Medicine Technology:Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4Regulatory Affairs for Support Staff Seminar (London, UK - September 24-25, 2015) 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 3Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 4Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 5Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 6Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 7Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 8Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 9
(Date:9/1/2015)... ... September 01, 2015 , ... Plaza OBGYN in Houston, ... Touch® , an innovative vaginal health laser procedure that prevents and resolves dryness ... for atrophic vaginitis, a condition that causes vaginal dryness, pelvic discomfort, painful intercourse ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... real-time monitoring and analysis of pet vital signs and activity, today announced its ... one of the most popular and widely-adopted veterinary hospital Practice Management Software packages ...
(Date:9/1/2015)... ME (PRWEB) , ... September 01, 2015 , ... Royal ... large, new study that followed men and women for 19 years and found that, ... who did not take multivitamins. , The report is part of the September 2015 ...
(Date:9/1/2015)... D.C. (PRWEB) , ... September 01, 2015 , ... Two ... better cross cultural relations through food and dining. , Recently named “the next ... and Luigi Diotaiuti are known for telling the whole story behind food and reclaiming ...
(Date:9/1/2015)... ... September 01, 2015 , ... METTLER TOLEDO ... available. With the Connectivity Kit, EasySampler data is automatically transferred to, and ... experiment, on a touchscreen platform. , EasySampler fully automates the sampling process ...
Breaking Medicine News(10 mins):Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 4Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 2Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 3
... Among First to Carry New Package, ATLANTA, March ... It! fortified juice beverage for kids, announced today the ... to five all natural,fruit-filled beverages. Shaw,s, ShopRite and Pathmark, ... will be among a host of leading,retailers to introduce ...
... reveals that people who wear glasses are not stereotypical ... myth that people who wear glasses are introverted or ... to be agreeable and open, rather than closed and ... Melbournes Centre for Eye Research Australia. , Myopia or ...
... that focus on usability and ... rapid commercialization, ... product design and development company, serving the life,sciences industry, today ... Research & Development. As the company continues to,expand, Dan furthers ...
... savor the ... health benefits of soy, NORTHRIDGE, Calif., ... to fall in love with soy -- Strawberry and Peanut,Chocolate Chip ... ranks of the original all-natural, baked flavors -- Apple,Walnut, Berry, Mango ...
... TAI,AN, China, March 25 /Xinhua-PRNewswire-FirstCall/ -- China ... CRUI) (,China,RuiTai, or ,the Company,), a leading ... the People,s Republic of China (,PRC,), today,announced ... design and execute its investor,relations campaign., ...
... Can Now Sleep Protected and at Ease With ... Asthma & Allergy Friendly(TM) Bedding, ... of innovative and premium home textile products, today,announced that several ... friendly(TM) by the Asthma and Allergy,Foundation of America (AAFA). This ...
Cached Medicine News:Health News:White Hat Brands Takes Dog On It! Fortified Juice Beverage for Kids to New Heights 2Health News:Mythbusted -- people who wear glasses aren't geeks 2Health News:Hiemstra Appoints Daniel C. Rosenman as Vice President of Research & Development 2Health News:SOYJOY(R) Introduces Two New Ways to Enjoy Soy 2Health News:China RuiTai International Holdings Retains CCG Elite for Investor Relations Services 2Health News:China RuiTai International Holdings Retains CCG Elite for Investor Relations Services 3Health News:London Luxury Receives Asthma & Allergy Friendly(TM) Certification for Several of Its Bedding Products 2Health News:London Luxury Receives Asthma & Allergy Friendly(TM) Certification for Several of Its Bedding Products 3
Used to negotiate tortuous vessels....
BiodivYsio stent with biocompatible coating (phosphorylcholine)...
... The CYPHER Sirolimus-eluting Coronary Stent ... drug, called "sirolimus", a controlled-release ... delivery platform. Upon placement, sirolimus ... and impedes the process of ...
PT wires combine the enhanced durability of a linear elastic nitinol distal core and a highly resilient polymer tip. This provides excellent access in difficult cases involving severe tortuosity, tig...
Medicine Products: